Pursuant to Regulation 30 of the Listing Regulations, Gujarat Themis Biosyn has informed that the Board of Directors of the Company, at its meeting held today on Saturday, 4th November, 2023, has approved the following: The Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report is enclosed and the proposal to enter into Master Service Agreement with its Related Party, Themis Medicare. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. The meeting commenced at 10:00 and concluded at 11:15 am.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1545.25 |
Dr. Reddys Lab | 5861.00 |
Cipla | 1356.95 |
Zydus Lifesciences | 987.05 |
Lupin | 1635.00 |
View more.. |